IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkae437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Sabrina Fischer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Tumor Research (IMT), Philipps University of Marburg, Marburg 35043, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Transcription Factor AP-1, Inflammation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German José Carreras Leukemia Foundation, Fritz Thyssen Foundation, German Research Foundation.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a hematological malignancy characterized by abnormal proliferation and accumulation of immature myeloid cells in the bone marrow. Inflammation plays a crucial role in AML progression, but excessive activation of cell-intrinsic inflammatory pathways can also trigger cell death. IRF2BP2 is a chromatin regulator implicated in AML pathogenesis, although its precise role in this disease is not fully understood. In this study, we demonstrate that IRF2BP2 interacts with the AP-1 heterodimer ATF7/JDP2, which is involved in activating inflammatory pathways in AML cells. We show that IRF2BP2 is recruited by the ATF7/JDP2 dimer to chromatin and counteracts its gene-activating function. Loss of IRF2BP2 leads to overactivation of inflammatory pathways, resulting in strongly reduced proliferation. Our research indicates that a precise equilibrium between activating and repressive transcriptional mechanisms creates a pro-oncogenic inflammatory environment in AML cells. The ATF7/JDP2-IRF2BP2 regulatory axis is likely a key regulator of this process and may, therefore, represent a promising therapeutic vulnerability for AML. Thus, our study provides new insights into the molecular mechanisms underlying AML pathogenesis and identifies a potential therapeutic target for AML treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Biology and Tumor Research (IMT), Philipps University of Marburg, Marburg 35043, Germany.
- Department of Hematology, Oncology, and Immunology, University Hospital Giessen and Marburg, Marburg 35043, Germany.
- Translational Oncology Group, Center for Tumor Biology and Immunology (ZTI), Philipps University of Marburg, Marburg 35043, Germany.
- Protein Analysis Unit, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University (LMU) Munich, Martinsried 82152, Germany.
- Genomics Core Facility, Institute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University of Marburg, Marburg 35043, Germany.
ORCID-Profile: Ignasi Forné, Robert Liefke
Förderung
- German José Carreras Leukemia Foundation
- Fritz Thyssen Foundation
- German Research Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Fischer, S., Weber, L. M., Stielow, B., Frech, M., Simon, C., Geller, M., Könnecke, J., Finkernagel, F., Forné, I., Nist, A., Bauer, U. M., Stiewe, T., Neubauer, A., & Liefke, R. (2024). IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae437
Vancouver
Fischer S, Weber LM, Stielow B, Frech M, Simon C, Geller M, et al. IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae437
BibTeX
@article{Fischer2024,
author = {Fischer, Sabrina and Weber, Lisa Marie and Stielow, Bastian and Frech, Miriam and Simon, Clara and Geller, Merle and Könnecke, Julie and Finkernagel, Florian and Forné, Ignasi and Nist, Andrea and Bauer, Uta-Maria and Stiewe, Thorsten and Neubauer, Andreas and Liefke, Robert},
title = {IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkae437}
}
EUVIMED